STENTYS: Revenues for the 3rd Quarter 2011
STENTYS (Paris:STNT) (FR0010949404 – STNT), a medical technology company commercializing the world's first and only self-apposing stent to treat Acute Myocardial Infarction (AMI), today reports its third-quarter and nine-month year-to-date revenues until 30 September 2011.
- Quarterly and 9-month revenues
|In € thousands (unaudited)||YTD 2010 - 9 months||YTD 2011 - 9 months|
|In € thousands* (unaudited)||Q1 2011 - 3 months||Q2 2011 - 3 months||Q3 2011 - 3 months|
* the Company did not draw up quarterly results prior to its IPO, so a comparison with the first half of 2010 cannot be made
Revenues for the 3rd quarter of 2011 totalled €371.0k. The figure is up again compared to the second quarter of 2011, despite the traditional seasonal slowdown of the summer period. For the first 9 months of the year, total sales reached €970k.
Gonzague Issenmann, Chief Executive Officer and co-founder of STENTYS, concludes: "Stentys' self-apposing stents are continuing on a steep adoption curve, confirming the efficiency of the controlled release commercial strategy amongst Europe’s top hospitals. The milestone of a million euros in sales has thus been reached less than 18 months after marketing began. We reiterate our confidence in STENTYS’ continued development, which will be supported by the excellent preliminary results of the APPOSITION III clinical trial announced yesterday.”
- Next press release
STENTYS will publish its 2011 annual revenues on 25 January 2012, after market.
Based in Princeton, N.J., and Paris, Stentys has developed a new generation of stents to treat acute myocardial infarction (AMI). Founded by Jacques Séguin, M.D., Ph.D., and Gonzague Issenmann, Stentys received the CE mark for its flagship products in 2010. Its self-apposing stents adapt to the anatomic changes of the arteries in the post-infarction phase and thus prevent the malapposition problems associated with conventional stents. Stentys has commenced its marketing activities in several European countries.
More information on www.stentys.com.
|STENTYS is listed on Compartment C of the NYSE Euronext Paris|
|ISIN: FR0010949404 – Ticker: STNT|
Nachrichten zu STENTYSmehr Nachrichten
||STENTYS Revenues for the First 9 Months of 2012 up 88% over Prior Year (MotleyFool)|
||STENTYS: Financial Events: Agenda 2012 (Businesswire)|
||STENTYS: Revenues for the 3rd Quarter 2011 (Businesswire)|
||Outstanding Interim Results of STENTYS International Clinical Study of 600 Heart Attack Patients (Businesswire)|
Analysen zu STENTYSmehr Analysen
Inside Fonds (Anzeige)
SMI und DAX gehen schwächer ins Wochenende -- Wall Street geschlossen -- Asiens Börsen letztlich freundlich
Börse aktuell - Live Ticker
Die Schweizer Märkte sowie der DAX wurden am Freitag von Gewinnmitnahmen belastet. An den US-Aktienmärkten findet feiertagsbedingt kein Handel statt. Die Märkte in Fernost schlossen am Freitag Aufschlägen.